Abeona Therapeutics Inc. insider trading
Every open-market purchase and sale by Abeona Therapeutics Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Abeona Therapeutics Inc.’s insiders pay?
From May 16, 2012 to September 29, 2026, 21 insiders reported 22 open-market purchases and 60 sales not made under a pre-set plan in Abeona Therapeutics Inc. Twelve months after each purchase was reported, the shares were −22.9% against the S&P 500 on average (median −58.0%), over 7 purchases with a full year of prices; 14% beat the index. After sales, the shares moved −19.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 4, 2015 into $6,272 by November 2, 2026, −4.1% a year. It held shares 36% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,329 (+5.5% a year), and held throughout $43,442 (+14.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Alvino Mark | Director | 0 | — | — | 13 | −22.3% (5) | September 1, 2026 |
| O'malley Brendan M. | SVP, Chief Legal Officer | 4 | — | — | 7 | −20.1% (3) | September 29, 2026 |
| Vazzano Joseph Walter | Chief Financial Officer | 3 | — | — | 7 | −23.1% (4) | September 29, 2026 |
| Seshadri Vishwas | Chief Executive Officer | 3 | −16.0% (1) | 0% | 6 | −19.6% (2) | September 29, 2026 |
| Silverstein Christine Berni | Director | 0 | — | — | 5 | +1.1% (1) | June 15, 2026 |
| Vasanthavada Madhav | Chief Commercial Officer | 0 | — | — | 5 | — | September 29, 2026 |
| Wider Todd | Director | 2 | +55.5% (2) | 50% | 3 | — | October 8, 2021 |
| Alland Leila | Director | 1 | — | — | 3 | — | July 2, 2026 |
| Charles Faith L. | Director | 1 | — | — | 2 | +1.1% (1) | July 10, 2025 |
| Acm Capital Partners, LLC | 10% owner | 0 | — | — | 2 | — | June 29, 2012 |
| Ahn Mark J | Director | 2 | −58.0% (1) | 0% | 0 | — | August 3, 2015 |
| Buono Stefano | Director | 2 | −65.2% (1) | 0% | 0 | — | December 31, 2019 |
| Crombez Eric | Director | 0 | — | — | 2 | −32.2% (1) | February 2, 2026 |
| Mann Paul Elliot | Director | 0 | — | — | 2 | — | February 23, 2021 |
| Amoroso Michael | Director | 0 | — | — | 1 | — | September 29, 2023 |
| Carr Edward | Chief Accounting Officer | 0 | — | — | 1 | — | March 20, 2020 |
| Howell Stephen B. | Director | 1 | −66.2% (1) | 0% | 0 | — | April 10, 2019 |
| Jeffrey B Davis | Director | 1 | — | — | 0 | — | December 29, 2014 |
| Rouhandeh Steven H | Director | 1 | — | — | 0 | — | December 29, 2014 |
| Van Duyne Richard B | Director | 1 | −66.3% (1) | 0% | 0 | — | April 18, 2019 |
| Wuchterl Donald A. | Director | 0 | — | — | 1 | — | February 2, 2026 |
When several insiders traded Abeona Therapeutics Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Abeona Therapeutics Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −70.8% against the index. After 2 selling crowds, −0.9%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 30, 2026 | 5 selling | −19.1% | not yet | not yet |
| January 30, 2026 | 5 selling | +2.3% | +15.5% | not yet |
| June 30, 2025 | 4 selling | −13.9% | −17.4% | −15.5% |
| April 30, 2019 | 3 buying | −64.1% | −70.8% | −68.5% |